Bedside Rounds

Staphylococcus aureus bacteremia: workup and management

Every S. aureus bloodstream isolate is real until proven otherwise. Infectious diseases consultation reduces mortality. Find and control the source, repeat cultures until clear, echocardiogram for all, and treat for at least 14 days from the first negative culture (4–6 weeks if complicated).

Working diagnosis Adult · US guidelines Draft · awaiting physician review
Tailor to a patient with AI Bedside calculators Report an error

01Orient

What's new in the evidence

  • DOTS (2025): dalbavancin 1500 mg on days 1 and 8 after initial therapy for complicated S. aureus bacteremia was similar to standard IV therapy in efficacy
  • BALANCE (2025) 7-day bacteremia courses do not apply to S. aureus
  • Ceftobiprole was FDA-approved in 2024 for S. aureus bacteremia including right-sided endocarditis
  • Cefazolin is at least as effective as antistaphylococcal penicillins for MSSA with less toxicity

Differential diagnoses

  1. Uncomplicated bacteremia with a removable source (catheter)
  2. Infective endocarditis (can't miss)
  3. Vertebral osteomyelitis, epidural abscess, septic arthritis (can't miss)
  4. Septic thrombophlebitis, deep abscess, psoas abscess
  5. Device or prosthetic joint infection
  6. Contaminant (very rare for S. aureus)

02Assess

Risk scores and decision tools

  • Uncomplicated criteria: endocarditis excluded, no prosthetics, cultures clear within 72 h, afebrile within 72 h, no metastatic foci
  • VIRSTA score for need for TEE
  • PREDICT or POSITIVE scores for TEE decisions

Key history questions

  • Indwelling catheters, dialysis access, recent procedures
  • Injection drug use
  • Prosthetic valves, joints, devices, vascular grafts
  • Back pain, joint pain, neurological symptoms
  • Skin or soft tissue infection

Examination findings

  • Line sites, skin and soft tissue
  • New murmur, embolic phenomena
  • Spinal tenderness, neurological deficits
  • Joint effusions

03Investigate

Initial investigations

  • Repeat blood cultures every 24–48 hours until negative
  • Transthoracic echocardiogram for all; TEE if high risk (prosthetic valve, device, persistent bacteremia, injection drug use, community-acquired without source)
  • CBC, BMP, LFTs, CRP; MRSA/MSSA rapid PCR on the positive bottle

Advanced investigations

  • MRI spine for back pain; imaging of any symptomatic site
  • FDG PET/CT for persistent bacteremia without a source

04Treat

Immediate management

  • Start vancomycin (AUC-guided) until susceptibilities return
  • Remove infected central lines; drain abscesses
  • Infectious diseases consultation for every patient

First-line treatment

  • MSSA: cefazolin 2 g IV every 8 hours (or nafcillin/oxacillin)
  • MRSA: vancomycin (AUC 400–600) or daptomycin 8–10 mg/kg/day
  • Uncomplicated: at least 14 days from the first negative culture
  • Complicated: 4–6 weeks; longer for osteomyelitis

Second-line treatment

  • Persistent MRSA bacteremia: high-dose daptomycin, often combined with ceftaroline or another beta-lactam, plus source search
  • Selected stable patients: oral step-down (e.g., linezolid or TMP-SMX) or dalbavancin with ID input
  • No routine adjunctive rifampin or gentamicin for native-valve disease

Specialist referrals

  • Infectious diseases (mandatory)
  • Cardiology/cardiac surgery if endocarditis
  • Spine surgery for epidural abscess

05Disposition

Admission criteria

  • All S. aureus bacteremia

Safe discharge criteria

  • Cultures cleared, source controlled, echo done
  • OPAT or approved oral regimen with ID follow-up

Follow-up timing

  • ID clinic during therapy; weekly labs

Patient instructions

  • Report fever, back pain or new symptoms

Monitoring

  • Blood cultures until negative
  • Weekly CBC, BMP, LFT, CK on daptomycin, vancomycin AUC

Clinical pearls and pitfalls

  • Mortality is 20–30%; ID consultation, echocardiography and source control are evidence-based quality measures
  • Duration counts from the first negative culture
  • CAMERA2: adding a beta-lactam to vancomycin or daptomycin for MRSA did not improve outcomes and increased AKI

RefGuidelines and landmark evidence

For education only. Typical adult starting points; confirm doses against renal function, allergies, interactions and your institution's protocols. Not a substitute for clinical judgment or senior review.

Acetaminophen overdoseAcute abdominal painAcute aortic dissectionAcute cholangitis and choledocholithiasisAcute decompensated heart failureAcute diverticulitisAcute dizziness and vertigoAcute ischemic stroke and TIAAcute kidney injuryAcute pancreatitisAcute pericarditisAdrenal crisisAlcohol withdrawalAlcohol-associated hepatitisAnaphylaxisAnemia in hospitalized adultsAsthma exacerbationAtrial fibrillation with rapid ventricular responseBacterial meningitisCellulitisChest painClostridioides difficile infectionCommunity-acquired pneumoniaCOPD exacerbationDecompensated cirrhosis (ascites, SBP, hepatic encephalopathy)Deep vein thrombosisDelirium / acute confusionDiabetic foot infection and osteomyelitisDiabetic ketoacidosisFebrile neutropeniaFirst seizure and status epilepticusHypercalcemiaHyperglycemia in hospitalized adultsHyperkalemiaHypernatremiaHyperosmolar hyperglycemic state (HHS)Hypertensive emergencyHypoglycemiaHypokalemiaHyponatremiaInfective endocarditisLower GI bleedMajor bleeding on anticoagulants (reversal)Malignant spinal cord compressionNSTEMI and non-ST-elevation ACSOpioid overdose and opioid use disorderPulmonary embolismPyelonephritis and complicated UTIRhabdomyolysisSepsisShortness of breathSickle cell vaso-occlusive crisisSymptomatic bradycardia and heart blockSyncopeThrombocytopenia (including TTP, HIT and ITP)Thunderclap headache (rule out subarachnoid hemorrhage)Thyroid stormTumor lysis syndromeUpper GI bleed